# Fasudil fOr redUcing elopemeNt and Spatial Disorientation

> **NCT04793659** · PHASE2 · COMPLETED · sponsor: **Woolsey Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Dementia

## Interventions

- **DRUG:** Oral Fasudil 90 mg/day
- **DRUG:** Oral Fasudil 180 mg/day
- **DRUG:** Oral Placebo

## Key facts

- **NCT ID:** NCT04793659
- **Lead sponsor:** Woolsey Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-15
- **Primary completion:** 2021-12-08
- **Final completion:** 2022-02-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04793659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04793659, "Fasudil fOr redUcing elopemeNt and Spatial Disorientation". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04793659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*